{"id":{"repo_id":"uiuc","oai_identifier":"oai:www.ideals.illinois.edu:2142/72250"},"canonical_url":"https://search.dev.ndltd.org/etd/uiuc/oai:www.ideals.illinois.edu:2142/72250","repository":{"repo_id":"uiuc","name":"University of Illinois - Urbana-Champaign","base_url":"https://www.ideals.illinois.edu/oai-pmh"},"display":{"title":"Synthesis of Saponin Immunoadjuvants","abstract":"The clinical success of conjugate anticancer and antiviral vaccines critically depends on the identification of, and access to, novel adjuvants with high potency and attenuated toxicity. The QS-21 fraction of Quillaja saponaria extracts comprises an isomeric mixture of complex triterpene saponins and is currently the most promising immunopotentiator in several antitumor and infectious disease vaccine therapies. However, the clinical use of QS-21 has been hindered by the difficulty in obtaining sufficient quantities of homogenous saponin from the natural source as well as by the low-grade toxicity and hydrolytic instability of this adjuvant. In this work, a robust chemical route to the two principal isomeric constituents of QS-21 has been established, and synthetically pure adjuvant has been prepared to fuel several pilot trials. In addition, an improved semisynthetic route to pure QS-saponin adjuvants has been developed, facilitating the discovery of novel immunostimulants with increased potency, stability and attenuated toxicity. This method was applied to the synthesis of the natural product adjuvant QS-7-Api and to non-natural aza-saponins. In this initial foray into designed molecular adjuvants, hydrolytically stable saponins have been discovered that equal or excel QS-21 as immunoadjuvants.","abstract_html":"The clinical success of conjugate anticancer and antiviral vaccines critically depends on the identification of, and access to, novel adjuvants with high potency and attenuated toxicity. The QS-21 fraction of Quillaja saponaria extracts comprises an isomeric mixture of complex triterpene saponins and is currently the most promising immunopotentiator in several antitumor and infectious disease vaccine therapies. However, the clinical use of QS-21 has been hindered by the difficulty in obtaining sufficient quantities of homogenous saponin from the natural source as well as by the low-grade toxicity and hydrolytic instability of this adjuvant. In this work, a robust chemical route to the two principal isomeric constituents of QS-21 has been established, and synthetically pure adjuvant has been prepared to fuel several pilot trials. In addition, an improved semisynthetic route to pure QS-saponin adjuvants has been developed, facilitating the discovery of novel immunostimulants with increased potency, stability and attenuated toxicity. This method was applied to the synthesis of the natural product adjuvant QS-7-Api and to non-natural aza-saponins. In this initial foray into designed molecular adjuvants, hydrolytically stable saponins have been discovered that equal or excel QS-21 as immunoadjuvants.","abstract_has_math":false,"creators":["Adams, Michelle Marie"],"institution":"University of Illinois at Urbana-Champaign","degree_name":"Ph.D.","degree_level":"Dissertation","degree_discipline":"Chemistry","degree_department":null,"school":null,"contributors":["Gin, David Y."],"advisors":[],"committee_chairs":[],"committee_members":[],"year":2014,"date_issued":"2014-12-17T21:28:51Z","date_published":"2014-12-17T21:28:51Z","updated_at":"2026-07-22T22:26:06Z","subjects":["Chemistry, Organic","Health Sciences, Immunology"],"languages":[],"rights":[],"rights_urls":[],"identifier_entries":[{"key":"dc:identifier","label":"Identifier","values":["(UMI)AAI3362712"],"render_values":[{"text":"(UMI)AAI3362712","href":null,"code":true}]}]},"links":{"outbound_url":"http://hdl.handle.net/2142/72250","outbound_label":"Handle","outbound_source":"dc:identifier"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:contributor","label":"Contributor","values":["Gin, David Y."]},{"key":"dc:creator","label":"Author","values":["Adams, Michelle Marie"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date","label":"Dc Date","values":["2014-12-17T21:28:51Z","10000-01-01","2009"]},{"key":"dc:type","label":"Dc Type","values":["text"]},{"key":"thesis:degree_discipline","label":"Discipline","values":["Chemistry"]},{"key":"thesis:degree_level","label":"Degree Level","values":["Dissertation"]},{"key":"thesis:degree_name","label":"Degree Name","values":["Ph.D."]},{"key":"thesis:institution_name","label":"Thesis Institution Name","values":["University of Illinois at Urbana-Champaign"]}]},{"id":"subjects_keywords","label":"Subjects and Keywords","entries":[{"key":"dc:subject","label":"Dc Subject","values":["Chemistry, Organic","Health Sciences, Immunology"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier","label":"Identifier","values":["http://hdl.handle.net/2142/72250","(UMI)AAI3362712"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description","label":"Description","values":["The clinical success of conjugate anticancer and antiviral vaccines critically depends on the identification of, and access to, novel adjuvants with high potency and attenuated toxicity. The QS-21 fraction of Quillaja saponaria extracts comprises an isomeric mixture of complex triterpene saponins and is currently the most promising immunopotentiator in several antitumor and infectious disease vaccine therapies. However, the clinical use of QS-21 has been hindered by the difficulty in obtaining sufficient quantities of homogenous saponin from the natural source as well as by the low-grade toxicity and hydrolytic instability of this adjuvant. In this work, a robust chemical route to the two principal isomeric constituents of QS-21 has been established, and synthetically pure adjuvant has been prepared to fuel several pilot trials. In addition, an improved semisynthetic route to pure QS-saponin adjuvants has been developed, facilitating the discovery of novel immunostimulants with increased potency, stability and attenuated toxicity. This method was applied to the synthesis of the natural product adjuvant QS-7-Api and to non-natural aza-saponins. In this initial foray into designed molecular adjuvants, hydrolytically stable saponins have been discovered that equal or excel QS-21 as immunoadjuvants.","Made available in DSpace on 2014-12-17T21:28:51Z (GMT). No. of bitstreams: 1 3362712.pdf: 7740867 bytes, checksum: bbf89da5712c04038a0b5811524ca9dd (MD5) Previous issue date: 2009","Embargo set by: Seth Robbins for item 72418 Lift date: Forever Reason: Restricted to the U of I community idenfinitely during batch ingest of legacy ETDs","Restricted to the U of I community idenfinitely during batch ingest of legacy ETDs","U of I Only","360 p.","Thesis (Ph.D.)--University of Illinois at Urbana-Champaign, 2009."]},{"key":"dc:title","label":"Title","values":["Synthesis of Saponin Immunoadjuvants"]}]}],"canonical_facts":{"dc:contributor":["Gin, David Y."],"dc:creator":["Adams, Michelle Marie"],"dc:date":["2014-12-17T21:28:51Z","10000-01-01","2009"],"dc:description":["The clinical success of conjugate anticancer and antiviral vaccines critically depends on the identification of, and access to, novel adjuvants with high potency and attenuated toxicity. The QS-21 fraction of Quillaja saponaria extracts comprises an isomeric mixture of complex triterpene saponins and is currently the most promising immunopotentiator in several antitumor and infectious disease vaccine therapies. However, the clinical use of QS-21 has been hindered by the difficulty in obtaining sufficient quantities of homogenous saponin from the natural source as well as by the low-grade toxicity and hydrolytic instability of this adjuvant. In this work, a robust chemical route to the two principal isomeric constituents of QS-21 has been established, and synthetically pure adjuvant has been prepared to fuel several pilot trials. In addition, an improved semisynthetic route to pure QS-saponin adjuvants has been developed, facilitating the discovery of novel immunostimulants with increased potency, stability and attenuated toxicity. This method was applied to the synthesis of the natural product adjuvant QS-7-Api and to non-natural aza-saponins. In this initial foray into designed molecular adjuvants, hydrolytically stable saponins have been discovered that equal or excel QS-21 as immunoadjuvants.","Made available in DSpace on 2014-12-17T21:28:51Z (GMT). No. of bitstreams: 1 3362712.pdf: 7740867 bytes, checksum: bbf89da5712c04038a0b5811524ca9dd (MD5) Previous issue date: 2009","Embargo set by: Seth Robbins for item 72418 Lift date: Forever Reason: Restricted to the U of I community idenfinitely during batch ingest of legacy ETDs","Restricted to the U of I community idenfinitely during batch ingest of legacy ETDs","U of I Only","360 p.","Thesis (Ph.D.)--University of Illinois at Urbana-Champaign, 2009."],"dc:identifier":["http://hdl.handle.net/2142/72250","(UMI)AAI3362712"],"dc:subject":["Chemistry, Organic","Health Sciences, Immunology"],"dc:title":["Synthesis of Saponin Immunoadjuvants"],"dc:type":["text"],"thesis:degree_discipline":["Chemistry"],"thesis:degree_level":["Dissertation"],"thesis:degree_name":["Ph.D."],"thesis:institution_name":["University of Illinois at Urbana-Champaign"]},"updated_at":"2026-07-22T22:26:06Z"}